Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Biofortuna Raise £1.3m Of Investment For Growth In Its Freeze Dried Molecular Diagnostics BusinessBiofortuna, a UK based molecular diagnostics company with a proprietary stabilisation technology for molecular reagents, is expanding its custom service and manufacturing business with a £1.3m investment.
By: Biofortuna The funding was supported by all of the company’s current investors; the Foresight Group (UK), EV Group, Catapult Venture Managers, Merseyside Special Investment Fund, private investorsand management. Biofortuna (http://www.biofortuna.com/) Biofortuna’s unique stabilisation approach means that all reagents are premixed and freeze dried so that the end user is only required to add the patient’s DNA sample which makes the test simple, quick and easy whilst reducing cost and manual errors. Additionally the kits can be stored and transported at ambient temperature, eliminating the need for fridges, freezers and temperature controlled shipping. The company is offering its technology, together with its design, development and manufacturing capability, on a custom service basis to clients who want to convert kits to a stabilised format and are working with a wide range of companies to give them a competitive edge in the market place. Biofortuna also has its own range of stabilised products, SSPGoTM, for the transplantation, disease ID and PGx market and has partnered with Abbott Molecular as a global exclusive distributor for these kits. Dr Simon Douglas, CEO of Biofortuna (http://www.biofortuna.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|